Integer Operating Income Falls 50% To $28 Million As Two New Electrophysiology Products Hit Sales

The medical device maker, being bought by a KKR-managed affiliate, posted $450 million in third-quarter sales and gave no outlook.

Share
Integer Operating Income Falls 50% To $28 Million As Two New Electrophysiology Products Hit Sales

Integer Holdings, which makes medical device components and finished devices for other companies, said third-quarter sales fell 3.9% to $450 million and operating income was cut in half to $28 million, according to an 8-K filed Thursday. The company is being acquired by an affiliate of investment funds managed by KKR, and it will not give an outlook or hold an earnings call.

Profit falls faster than sales

Organic sales, which strip out currency swings, acquisitions and the exit from Portable Medical, fell 2.2%. Operating income under standard accounting dropped 50% from $56 million a year earlier, and diluted earnings per share from continuing operations fell 61% to $0.43.

On an adjusted basis, which excludes items such as amortization and restructuring, earnings were $1.34 per share, down 25%. Adjusted EBITDA, a measure of operating cash earnings, fell 17% to $88 million.

For the first nine months of 2026, operating income fell 42.8% to about $94.6 million from about $165.3 million a year earlier. Sales for the nine months were down 2.0%.

Electrophysiology launches weigh on Cardio & Vascular

Cardio & Vascular sales fell 5% to $263 million, which the company tied to the previously communicated impact of two new Electrophysiology products. Cardiac Rhythm Management & Neuromodulation rose 4% to $176 million, though one new Neuromodulation product partly offset that growth.

Other Markets sales fell to $11 million from $21 million, mainly because of the Portable Medical exit.

Integer makes catheters, guidewires, heart-valve delivery components, and batteries and feedthroughs for implanted pacemakers and nerve stimulators. Its customers are mainly large medical device makers; in 2025, Abbott Laboratories, Boston Scientific and Medtronic each exceeded 10% of sales and together made up 49%.

Debt up, KKR deal on track

Total debt rose $34 million from the end of 2025 to $1.219 billion, leaving leverage at 3.3 times adjusted EBITDA as of October 2, 2026.

The company received early termination of the Hart-Scott-Rodino antitrust waiting period on September 29, and stockholders approved the merger agreement on October 21. The merger agreement is dated August 2, 2026. Integer anticipates the deal will close by the end of 2026, subject to remaining closing conditions, including required regulatory approvals.

Integer expects the KKR-affiliate acquisition to close by the end of 2026, which is why no outlook or call accompanied these results.

Sources

More on Integer Holdings

All Integer Holdings (ITGR) coverage →